المؤلفون: Li W, Daoud SZ, Trivedi R, Lukka PB, Jimenez E, Molins E, Stewart C, Bharali P, Garcia-Gil E

المصدر: International Journal of COPD, Vol Volume 18, Pp 2725-2735 (2023)

مصطلحات موضوعية: aclidinium bromide, bronchodilator, china, chronic obstructive pulmonary disease, pharmacokinetics, safety., Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.dovepress.com/the-pharmacokinetics-safety-and-tolerability-of-aclidinium-bromide-400-peer-reviewed-fulltext-article-COPD; https://doaj.org/toc/1178-2005

URL الوصول: https://doaj.org/article/a51ba7c6b7f74451b7e61ba5203fbd12

المؤلفون: Wise RA, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D, Garcia-Gil E

المصدر: International Journal of COPD, Vol Volume 16, Pp 689-699 (2021)

مصطلحات موضوعية: copd, copd exacerbation, aclidinium, mace, mortality, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

Relation: https://www.dovepress.com/the-impact-of-exacerbation-history-on-the-safety-and-efficacy-of-aclid-peer-reviewed-article-COPD; https://doaj.org/toc/1178-2005

URL الوصول: https://doaj.org/article/1c6bd4f87d314c30815f65aef5374cde

المؤلفون: Paz RD, Andreasen NC, Daoud SZ, Conley R, Roberts R, Bustillo J, Perrone-Bizzozero NI

المصدر: American Journal of Psychiatry; Oct2006, Vol. 163 Issue 10, p1829-1831, 3p

المؤلفون: Sun Y; Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China., Molins E; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Daoud SZ; Late Respiratory & Immunology, BioPharmaceuticals R&D, Gaithersburg, MD, USA. Electronic address: Sami.Daoud@astrazeneca.com., Trivedi R; Late Respiratory & Immunology, BioPharmaceuticals R&D, Durham, NC, USA., Stewart C; Statistics, Phastar, Chiswick, London, UK., Lamarca R; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Bharali P; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Pvt. Ltd, Bangalore, India., Garcia-Gil E; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.

المصدر: Respiratory medicine [Respir Med] 2023 Nov; Vol. 218, pp. 107393. Date of Electronic Publication: 2023 Aug 26.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE

مواضيع طبية MeSH: Bronchodilator Agents*/adverse effects , Bronchodilator Agents*/therapeutic use , Pulmonary Disease, Chronic Obstructive*/drug therapy, Humans ; Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Double-Blind Method ; East Asian People ; Forced Expiratory Volume ; Formoterol Fumarate/adverse effects ; Formoterol Fumarate/therapeutic use ; Muscarinic Antagonists/adverse effects ; Muscarinic Antagonists/therapeutic use ; Treatment Outcome ; Tropanes/adverse effects ; Tropanes/therapeutic use

المؤلفون: Rivero-Ferrer E; RTI Health Solutions, Pharmacoepidemiology and Risk Management, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain. erivero@rti.org., Olesen M; Department of Public Health, University of Southern Denmark, Clinical Pharmacology, Pharmacy, and Environmental Medicine, Odense, Denmark., Plana E; RTI Health Solutions, Biostatistics, Barcelona, Spain., Aguado J; RTI Health Solutions, Biostatistics, Barcelona, Spain., Saigí-Morgui N; RTI Health Solutions, Pharmacoepidemiology and Risk Management, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain., Rubino A; Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK., Daoud SZ; BioPharmaceuticals Research and Development, Late-Stage Development Research and Innovation, AstraZeneca, Gaithersburg, MD, USA., Lei A; Patient Safety Biopharma, Chief Medical Office, AstraZeneca, Barcelona, Spain., Perez-Gutthann S; RTI Health Solutions, Pharmacoepidemiology and Risk Management, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain., Schink T; Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany., Kristiansen NS; Department of Public Health, University of Southern Denmark, Clinical Pharmacology, Pharmacy, and Environmental Medicine, Odense, Denmark., Hallas J; Department of Public Health, University of Southern Denmark, Clinical Pharmacology, Pharmacy, and Environmental Medicine, Odense, Denmark., Pottegård A; Department of Public Health, University of Southern Denmark, Clinical Pharmacology, Pharmacy, and Environmental Medicine, Odense, Denmark., Rebordosa C; RTI Health Solutions, Pharmacoepidemiology and Risk Management, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain.

المصدر: Clinical drug investigation [Clin Drug Investig] 2022 Apr; Vol. 42 (4), pp. 319-331. Date of Electronic Publication: 2022 Mar 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE

مواضيع طبية MeSH: Adrenergic beta-2 Receptor Agonists*/therapeutic use , Pulmonary Disease, Chronic Obstructive*/diagnosis , Pulmonary Disease, Chronic Obstructive*/drug therapy , Pulmonary Disease, Chronic Obstructive*/epidemiology, Administration, Inhalation ; Adult ; Bronchodilator Agents ; Denmark ; Formoterol Fumarate ; Humans ; Muscarinic Antagonists/therapeutic use ; Tropanes/adverse effects ; Tropanes/therapeutic use ; United Kingdom/epidemiology

المؤلفون: Zhang H; Phase I Clinical Trial Unit, The First Hospital, Jilin University, No 71, Xinmin Street, Changchun, 130021, China., Daoud SZ; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Gillen MS; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Calderon N; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Heijer M; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Molins E; BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Garcia-Gil E; BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Chen H; Phase I Clinical Trial Unit, The First Hospital, Jilin University, No 71, Xinmin Street, Changchun, 130021, China., Li Q; Phase I Clinical Trial Unit, The First Hospital, Jilin University, No 71, Xinmin Street, Changchun, 130021, China., Liu C; Phase I Clinical Trial Unit, The First Hospital, Jilin University, No 71, Xinmin Street, Changchun, 130021, China., Ding Y; Phase I Clinical Trial Unit, The First Hospital, Jilin University, No 71, Xinmin Street, Changchun, 130021, China. dingyanh@jlu.edu.cn.

المصدر: Drugs in R&D [Drugs R D] 2022 Mar; Vol. 22 (1), pp. 35-42. Date of Electronic Publication: 2022 Feb 08.

نوع المنشور: Clinical Trial; Journal Article

بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-6901 (Electronic) Linking ISSN: 11745886 NLM ISO Abbreviation: Drugs R D Subsets: MEDLINE

مواضيع طبية MeSH: Pulmonary Disease, Chronic Obstructive*/drug therapy , Tropanes*/adverse effects , Tropanes*/pharmacokinetics, Administration, Inhalation ; Asian People ; Bronchodilator Agents ; Female ; Formoterol Fumarate/adverse effects ; Humans ; Male ; Middle Aged ; Muscarinic Antagonists

المؤلفون: Chapman KR; Asthma and Airway Centre, University of Toronto, Toronto, ON, Canada. kchapman@ca.inter.net.; Asthma and Airway Centre, University Health Network, 7th Floor East Wing, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada. kchapman@ca.inter.net., Wise RA; Pulmonary Function Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Scirica BM; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Bhatt DL; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Daoud SZ; Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Lythgoe D; Statistics, Phastar, Chiswick, London, UK., Gil EG; Formerly of AstraZeneca, Barcelona, Spain.

المصدر: Respiratory research [Respir Res] 2021 Oct 22; Vol. 22 (1), pp. 272. Date of Electronic Publication: 2021 Oct 22.

نوع المنشور: Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE

مواضيع طبية MeSH: Adrenergic beta-Antagonists/*therapeutic use , Lung/*drug effects , Muscarinic Antagonists/*therapeutic use , Pulmonary Disease, Chronic Obstructive/*drug therapy , Tropanes/*therapeutic use, Adrenergic beta-Antagonists/adverse effects ; Aged ; Canada ; Disease Progression ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/mortality ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Recovery of Function ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Tropanes/adverse effects ; United States ; Vital Capacity

المؤلفون: Wise RA; Pulmonary and Critical Care, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD, 21224, USA. rwise@jhmi.edu., Scirica BM; Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bhatt DL; Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Daoud SZ; Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Chuecos F; Late-Stage Development, Respiratory and Immunology-Biometrics, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Garcia Gil E; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Barcelona, Spain., Chapman KR; University of Toronto, Toronto, ON, Canada.

المصدر: Advances in therapy [Adv Ther] 2021 Oct; Vol. 38 (10), pp. 5381-5397. Date of Electronic Publication: 2021 Sep 15.

نوع المنشور: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther

مواضيع طبية MeSH: Adrenergic beta-2 Receptor Agonists*/therapeutic use , Pulmonary Disease, Chronic Obstructive*/drug therapy, Administration, Inhalation ; Bronchodilator Agents/therapeutic use ; Forced Expiratory Volume ; Humans ; Muscarinic Antagonists/therapeutic use ; Tropanes/therapeutic use

المؤلفون: Wise RA; Johns Hopkins University School of Medicine, Baltimore, Maryland., Chapman KR; University of Toronto, Toronto, Ontario, Canada., Scirica BM; Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Bhatt DL; Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Daoud SZ; AstraZeneca Research and Development Centre, Gaithersburg, Maryland., Zetterstrand S; AstraZeneca Research and Development, Bioinformatics and Information Sciences, Mölndal, Sweden., Reisner C; AstraZeneca Research and Development Centre, Gaithersburg, Maryland., Gil EG; AstraZeneca Research and Development Centre, Barcelona, Spain.

المصدر: JAMA [JAMA] 2019 May 07; Vol. 321 (17), pp. 1693-1701.

نوع المنشور: Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

مواضيع طبية MeSH: Cardiovascular Diseases/*chemically induced , Muscarinic Antagonists/*therapeutic use , Pulmonary Disease, Chronic Obstructive/*drug therapy , Tropanes/*therapeutic use, Administration, Inhalation ; Aged ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Patient Acuity ; Risk Factors ; Tropanes/adverse effects

المؤلفون: Wise RA; 1-Johns Hopkins University School of Medicine, Baltimore, Maryland., Chapman KR; 2-University of Toronto, Ontario, Canada., Scirica BM; 3-Brigham and Women's Hospital, Boston, Massachusetts.; 4-Harvard Medical School, Boston, Massachusetts., Schoenfeld DA; 4-Harvard Medical School, Boston, Massachusetts., Bhatt DL; 3-Brigham and Women's Hospital, Boston, Massachusetts.; 4-Harvard Medical School, Boston, Massachusetts., Daoud SZ; 5-AstraZeneca Research &Development Center, Gaithersburg, Maryland., Seoane B; 6-AstraZeneca Research & Development Centre, Barcelona, Spain., Reisner C; 5-AstraZeneca Research &Development Center, Gaithersburg, Maryland., Garcia Gil E; 6-AstraZeneca Research & Development Centre, Barcelona, Spain.

المصدر: Chronic obstructive pulmonary diseases (Miami, Fla.) [Chronic Obstr Pulm Dis] 2018 Jan 24; Vol. 5 (1), pp. 5-15. Date of Electronic Publication: 2018 Jan 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: COPD Foundation Country of Publication: United States NLM ID: 101635411 Publication Model: Electronic Cited Medium: Print ISSN: 2372-952X (Print) Linking ISSN: 2372952X NLM ISO Abbreviation: Chronic Obstr Pulm Dis Subsets: PubMed not MEDLINE